Over the past 12 months, Google’s efforts to use artificial intelligence have made a breakthrough in Human biology simulation and Senior scientists won the Nobel Prize in Chemistry.
Now, Isomorphic Labs, the section within the software giant, the development and marketing of technology, takes another big step: collecting money from an external investor.
Isomorphic plans to announce on Monday that it raised $ 600 million, led by Thrive Capital, the investment capital company that wanted to artificial intelligence companies including Openai. GV, Google’s Venture Capital Arm and Alphabet, the parent company of Google.
The advertisement confirms Google’s ambitions on ISOMORPHIC, which was directed by the company’s DeepMind Laboratory to focus on the discovery of medicines. It is based on the programs developed by DeepMind, the Central Intelligence Laboratory in London. This includes alphafold, which can expect millions of proteins and more.
Alphafold, which is in Its third repetition It can predict the complex behavior of the DNA and RNA, and it has promised to cut the time of the development of new drugs. This is her promise that Dimis Hasabis, co -founder of Isomorphic, DeepMind, and John M. Jumper, DeepMind researcher, participated in half of the Nobel in chemistry last year.
The goal, according to Mr. Hassabis, is to perform most of the drug detection process at the end via computers, instead of traditional laboratories that require biological materials and strict safety requirements – and a lot of time.
“This is the most beneficial application of Amnesty International there,” Mr. Hassan said in an interview. He added, “Our mission, one day, is to solve all diseases” with artificial intelligence
Isomorphic is researching potential treatments, including those that focus on cancerous and immunosuppressive disorders. Last year, research partnerships signed with two major drug makers, Eli Lilly and Novartis, which could result in billions of payments through promising drug breakthroughs.
But as with many AI’s things, work, and the employment of higher research talents for their performance is costly. Mr. Hassabis said that Isomorphic did not need capital – her mother company informed more than $ 100 billion in the past year – but it makes sense to bring an external partner.
Through Mr. Hassan’s thinking, doing this has long been a possibility. But he added that he wanted a constant supporter in the long run that was deeply focused on life sciences.
Additional funds will help expand the stability of research models such as Alphafold, as well as employ the best talents through scientific disciplines.
“The company’s ambition is to be a full life science company, which requires more capital to create more medicines while also investing in the technology platform,” Vince Hankes, the prosperous partner who led many AI’s investments.
Mr. Hassan added that he wants to be selective in Isomorphic partners; Official talks occurred with prosperity for months.
The collection of funds is another major bet by the 15 -year -old, who has invested in money in companies such as Instagram and the payment processor. Recently, it focused on artificial intelligence companies, including the leadership of A. The last round of Openai His evaluation has almost doubled to $ 157 billion, as well as Databrics analysis provider and Anysphere starting programming.
“Our hope is that AI radically changes the way the drugs are created and discovered,” said Joshua Kushner, the founder of Thrive and the administrative partner. “Isomorphic pays the limits of what is possible to discover small molecular drugs.”
Throughout the next year or so, isomorphic hopes that he has achieved more breaches in mathematical models such as Alphafold and may have drug candidates close to pre -clinical trials, Mr. Hassabis said.
He added that Isomorphic will collect money from more external investors. The goal is for the company to be an independent company.
“This will be one of the most proud companies about it,” he said. “We want to be a real power in this industry.”
